Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totaling 244,357 shares, a growth of 31.0% from the March 15th total of 186,549 shares. Based on an average trading volume of 369,603 shares, the short-interest ratio is currently 0.7 days. Currently, 2.4% of the company’s stock are sold short.

Calidi Biotherapeutics Stock Down 0.8%

Shares of CLDI stock traded down $0.00 during midday trading on Friday, reaching $0.28. 1,131,314 shares of the stock were exchanged, compared to its average volume of 451,507. Calidi Biotherapeutics has a 1 year low of $0.21 and a 1 year high of $19.20. The company’s 50 day moving average is $0.47 and its two-hundred day moving average is $1.05. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.21. The firm has a market cap of $3.00 million, a PE ratio of -0.04 and a beta of 1.42.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last posted its earnings results on Friday, March 27th. The company reported $0.45 earnings per share for the quarter. On average, equities research analysts predict that Calidi Biotherapeutics will post -4.48 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Warberg Asset Management LLC purchased a new stake in shares of Calidi Biotherapeutics in the 3rd quarter worth approximately $28,000. DRW Securities LLC purchased a new stake in shares of Calidi Biotherapeutics in the 4th quarter worth approximately $173,000. Geode Capital Management LLC grew its stake in shares of Calidi Biotherapeutics by 41.7% in the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after buying an additional 12,334 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Calidi Biotherapeutics in the 4th quarter worth approximately $25,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.